Growth is driven by the rising prevalence of diabetes among the elderly, necessitating efficient insulin delivery solutions ...

Researchers link GLP1 agonists to depression risk in some users and call for personalized prescribing based on genetic ...

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary endpoint of superior A1C reduction vs. placebo at 40 weeks.

A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and ...

Significant weight gain is a common side effect of many psychiatric medications. Fortunately, there are options for those who ...

DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well ...

Eli Lilly and Company announced on Friday positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

Diabetes Care. 2006;29(2):435-449.

Supervised lifestyle intervention from a medical professional may help maximize fat loss and minimize muscle tissue loss in ...

What else does weight-loss drug Ozempic do? 5 unexpected health benefits - Emerging scientific research indicates that ...